2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 583

Familial Aggregation and Heritability of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study
Abstract Number: 814

Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study
Abstract Number: 1182

Familial Aggregation and Heritability of Rheumatoid Arthritis in Taiwan: A Nationwide Population Study
Abstract Number: 2277

Familial Aggregation and Heritability of Systemic Lupus Erythematosus in Taiwan: A Nationwide Population Study
Abstract Number: 747

Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome.
Abstract Number: 1275

Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week 12
Abstract Number: 1292

Fatigue Is an Independent Variable Predicting Physical Function and Disease Activity Score-28 Remission for Patients with Rheumatoid Arthritis Treated with Intravenously Administered Golimumab: Results From Phase 3, Placebo Controlled Clinical Trial
Abstract Number: 317

Fatty Acid Profiling: Potential New Biomarkers in Juvenile Idiopathic Arthritis (pilot study)
Abstract Number: 891

Fatty Acids Promote Secretion of Proinflammatory and Prodestructive Factors by Synovial Fibroblasts
Abstract Number: 1417

Favorable Response to Belimumab At Three Months
Abstract Number: 1056

Fc Receptor Gamma-Dependent Autoimmune Endocarditis in K/BxN Mice
Abstract Number: 2160

Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis
Abstract Number: 132

FDG-PET Evaluation of Axillary Lymph Nodes and Large Joints of Patients with Rheumatoid Arthritis Treated with Anti-TNF Drugs
Abstract Number: 917

Feasibility of Remote Activity and Functional Status Monitoring of Patients with Hip or Knee Pain
Abstract Number: 817

Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].